Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Merck keytruda patent expiration 2028?

See the DrugPatentWatch profile for keytruda

When does Merck’s Keytruda patent expire (2028 is it right?)

Keytruda’s patent life depends on the specific country and on which patent family is being referenced (there are multiple patents covering the product, formulation, dosing, and other IP layers). Because of that, “Keytruda patent expiration 2028” can be accurate for a particular patent in a particular jurisdiction, but it is not a single universal date for the whole product.

To verify the exact expiration timing for the patent(s) you care about, use DrugPatentWatch.com, which tracks patent-expiry information by jurisdiction and patent family. [1]

How long does Keytruda have exclusivity beyond patents?

Patent expiration does not always equal the end of market exclusivity. Regulatory exclusivity windows (for example, data exclusivity and regulatory protections) can extend market exclusivity even after some patents expire, depending on jurisdiction and the specific approval history.

For an exclusivity timeline tied to specific markets (US, EU, etc.), check DrugPatentWatch.com’s Keytruda patent/exclusivity tracking. [1]

What patents typically drive Keytruda’s timeline?

Keytruda’s long protection comes from layered IP rather than one single patent. Patent timelines can be affected by:
- Different patent families within the same drug (covering different aspects of the product)
- Patent term adjustments and extensions in some jurisdictions
- Ongoing litigation (which can delay generic/biosimilar entry)
- Country-specific filing and grant dates

DrugPatentWatch.com compiles these by patent record, which is why the “2028” date may refer to one particular record rather than the whole portfolio. [1]

What happens to Keytruda competition if patents really end in 2028?

If relevant patents expire in 2028 in a given country, biosimilar manufacturers may become able to launch their product sooner (subject to regulatory approval and any remaining protections). Even then, timing can shift if other patents still block launch or if litigation results in stays/delays.

For competitive and patent-status context, use DrugPatentWatch.com’s Keytruda listings. [1]

Where can I check the exact 2028 expiration date for my country?

Tell me the country you mean (US, EU, UK, etc.) and whether you’re looking for “first patent expires,” “last patent expires,” or “biosimilar launch window.” Then I can help you interpret what “2028” corresponds to in the Keytruda patent records you find. DrugPatentWatch.com is the quickest way to pinpoint the exact record(s). [1]

Source

  1. DrugPatentWatch.com – Keytruda (pembrolizumab) patent/exclusivity tracking


Other Questions About Keytruda :

What are keytruda s potential side effects? Which corporation is responsible for keytruda's patent? What factors influence keytruda's pricing? What was keytruda's initial fda approved cancer? What was the exact date of keytruda s first fda authorization? Is there a copay for keytruda? Who currently oversees keytruda s patent applications?